Sunil Healthcare

Who are the top shareholders of the Sunil Healthcare?

The top shareholder of Sunil Healthcare is Anil Kumar Khaitan, who holds 57.95% of the shares. The highest public shareholder is Shailesh Kumar with 5.86%, while individual investors collectively own 17.85%.

The top shareholders of Sunil Healthcare are primarily the promoters, with Anil Kumar Khaitan holding the largest share at 57.95%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Shailesh Kumar, who owns 5.86% of the shares. Additionally, individual investors collectively hold 17.85% of the company's shares.

When is the next results date for Sunil Healthcare?

No Upcoming Board Meetings

Who are in the management team of Sunil Healthcare?

As of March 2021, the management team of Sunil Healthcare includes Anil Kumar Khaitan (Chairman & Managing Director), Sanjay Kumar Kaushik (Non-Executive Director), and several other directors and company secretaries, all contributing to the company's governance and strategic direction.

As of March 2021, the management team of Sunil Healthcare includes the following individuals:<BR><BR>1. Anil Kumar Khaitan - Chairman & Managing Director<BR>2. Sanjay Kumar Kaushik - Non Executive Director<BR>3. Rakesh Mohan - Non-Executive & Independent Director<BR>4. Santosh Kumar Sharma - Company Secretary<BR>5. Harish Pal Kumar - Non-Executive & Independent Director<BR>6. Krishna Venkatachalam Ranjan - Non-Executive & Non-Independent Director<BR>7. Mudita Chaturvedi - Additional Non-Executive Director<BR>8. Bejon Kumar Misra - Non-Executive & Independent Director<BR>9. Satyendu Pattnaik - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

What does Sunil Healthcare do?

Sunil Healthcare Ltd manufactures Empty Hard Gelatin Capsule Shells and HPMC Capsules, operating in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 21 Cr and a market cap of Rs 79 Cr.

Overview: <BR>Sunil Healthcare Ltd is a company engaged in the manufacturing of Empty Hard Gelatin Capsule Shells and HPMC Capsules Shell, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History: <BR>Incorporated in 1973, Sunil Healthcare Ltd was formerly known as Sunil Synchem Ltd. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 21 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 79 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.98 <BR>Return on Equity: -2.12% <BR>Price to Book: 1.19<BR><BR>Contact Details: <BR>Address: 38E/252-A 1st Flr, Vijay Tower Shahpurjat New Delhi New Delhi : 110049 <BR>Phone: 91-11-49435555 <BR>Email: info@sunilhealthcare.com <BR>Website: http://www.sunilhealthcare.com

Has Sunil Healthcare declared dividend?

No Dividend History Available

Who are the peers of the Sunil Healthcare?

Sunil Healthcare's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Vivo Bio Tech, Vasundhara Rasy, and Roopa Industries. Sunil Healthcare has below-average management risk and growth, with a 1-year return of -7.26%, better than Rajnish Wellness but lower than its other peers.

Peers: The peers of Sunil Healthcare are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Vivo Bio Tech, Vasundhara Rasy., Roopa Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Rajnish Wellness, Vivo Bio Tech, and Vasundhara Rasy. Below Average management risk is seen at Sunil Healthcare, Roopa Industries, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Rajnish Wellness, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Sunil Healthcare, Vivo Bio Tech, and the rest. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, Good for Torrent Pharma and Vasundhara Rasy., and Below Average for Sunil Healthcare, Rajnish Wellness, Vivo Bio Tech, Roopa Industries, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the peer with the lowest is Rajnish Wellness at -83.99%. Sunil Healthcare's 1-year return is -7.26%, which is higher than Rajnish Wellness but lower than all other peers. Additionally, the six-month return is negative for Rajnish Wellness, Vasundhara Rasy., and Sunil Healthcare.

What is the technical trend for Sunil Healthcare?

As of June 6, 2025, Sunil Healthcare's technical trend is mildly bearish, influenced by daily moving averages and a monthly MACD, despite mixed signals from the weekly MACD and Bollinger Bands.

As of 6 June 2025, the technical trend for Sunil Healthcare has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are mildly bearish, reinforcing the bearish stance. Bollinger Bands show a bullish signal on the weekly but a mildly bearish signal on the monthly, adding to the complexity. The KST is mildly bullish weekly but mildly bearish monthly, and there are no clear trends indicated by Dow Theory. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and the monthly MACD.

How big is Sunil Healthcare?

As of 24th July, Sunil Healthcare Ltd has a market capitalization of 83.00 Cr and reported Net Sales of 83.42 Cr, with a Net Profit loss of 1.42 Cr over the latest four quarters. Shareholder's Funds are 68.22 Cr and Total Assets are valued at 158.50 Cr as of March 2024.

As of 24th July, Sunil Healthcare Ltd has a market capitalization of 83.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 83.42 Cr. However, it experienced a loss of 1.42 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 68.22 Cr and Total Assets valued at 158.50 Cr.

How has been the historical performance of Sunil Healthcare?

Sunil Healthcare's historical performance shows a decline in net sales and profits, with net sales dropping from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25, and profit after tax turning negative from 6.68 Cr to -1.42 Cr. However, cash flow from operating activities improved from 7.00 Cr to 11.00 Cr during the same period.

Answer:<BR>The historical performance of Sunil Healthcare shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Sunil Healthcare's net sales have decreased from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25, reflecting a downward trend. The total operating income followed a similar pattern, dropping from 110.49 Cr in Mar'23 to 83.42 Cr in Mar'25. The company's total expenditure also declined from 94.33 Cr in Mar'23 to 73.16 Cr in Mar'25, indicating cost management efforts. Operating profit, which reached 20.66 Cr in Mar'23, fell to 11.60 Cr by Mar'25, while profit before tax transitioned from a positive 9.48 Cr in Mar'23 to a negative 1.22 Cr in Mar'25. Consequently, the profit after tax also turned negative, from 6.68 Cr in Mar'23 to -1.42 Cr in Mar'25. The company's total liabilities increased from 120.79 Cr in Mar'23 to 161.94 Cr in Mar'25, while total assets rose from 120.79 Cr to 161.94 Cr in the same period. Cash flow from operating activities showed improvement, moving from 7.00 Cr in Mar'23 to 11.00 Cr in Mar'25, despite the overall cash flow from financing activities being negative in Mar'25.

Is Sunil Healthcare overvalued or undervalued?

As of November 20, 2025, Sunil Healthcare is considered overvalued with a high PE ratio of 42.04 and an EV to EBITDA of 10.06, despite a low PEG ratio of 0.18, indicating inefficiencies in capital utilization and underperformance compared to industry peers and the Sensex.

As of 20 November 2025, Sunil Healthcare's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived value. The company is currently considered overvalued based on its high PE ratio of 42.04, which significantly exceeds the industry average. Additionally, its EV to EBITDA stands at 10.06, while its ROCE is only 5.00%, suggesting inefficiencies in capital utilization compared to peers.<BR><BR>In comparison to its industry peers, Sunil Healthcare's valuation metrics are notably higher; for instance, Sun Pharma has a PE ratio of 36.94 and an EV to EBITDA of 24.4, while Cipla, another attractive peer, has a PE of 22.72 and an EV to EBITDA of 16.07. The PEG ratio for Sunil Healthcare is also low at 0.18, indicating potential growth relative to its price, but this does not sufficiently offset the concerns raised by its high valuation ratios. Furthermore, the company's stock has underperformed relative to the Sensex over various time frames, including a year-to-date return of -9.08% compared to the Sensex's 9.59%.

Are Sunil Healthcare Ltd latest results good or bad?

Sunil Healthcare Ltd's latest results show a return to profitability with a net profit of ₹1.00 crore and revenue growth of 16.09% year-on-year; however, concerns remain due to low return on equity, high debt levels, and stock underperformance, suggesting caution for investors.

Sunil Healthcare Ltd's latest results present a mixed picture. On the positive side, the company has shown a return to profitability with a net profit of ₹1.00 crore in Q2 FY26, reflecting a 9.89% increase quarter-on-quarter. Additionally, revenue grew by 16.09% year-on-year to ₹23.52 crore, indicating a stabilizing demand for its gelatin capsule products after a challenging period.<BR><BR>The operating margin also improved significantly to 16.67%, up from 14.49% in the previous quarter, suggesting better operational efficiency. However, despite these improvements, there are significant concerns. The return on equity (ROE) remains low at 2.55%, indicating weak capital efficiency, and the company continues to face high debt levels, with a debt-to-EBITDA ratio of 6.68 times. This raises questions about its long-term viability and ability to service its debt.<BR><BR>Moreover, the stock has been underperforming, down 16.13% over the past year compared to the Sensex's gain of 7.07%. The technical indicators are also mildly bearish, with the stock trading below key moving averages.<BR><BR>In summary, while there are signs of operational recovery, the overall financial health of Sunil Healthcare is still concerning due to weak return ratios, high leverage, and persistent stock underperformance. Investors should weigh these factors carefully when considering the company's outlook.

Should I buy, sell or hold Sunil Healthcare Ltd?

Which are the latest news on Sunil Healthcare?

Why is Sunil Healthcare Ltd falling/rising?

As of 08-Feb, Sunil Healthcare Ltd's stock price is slightly rising at 69.61, with a recent gain attributed to positive quarterly results and outperformance against its sector. However, despite short-term gains, the stock has declined 16.13% over the past year, indicating uncertain long-term prospects.

As of 08-Feb, Sunil Healthcare Ltd's stock price is rising slightly, currently at 69.61, with a change of 0.06 (0.09%) upwards. This increase can be attributed to several factors. Notably, the stock has outperformed its sector by 0.89% today and has been on a consecutive gain streak for the last three days, accumulating a total return of 5.33% during this period. <BR><BR>Additionally, the company has reported positive results for the last four consecutive quarters, with a higher profit after tax of Rs 1.59 crore and a record return on capital employed (ROCE) of 6.69%. The stock is also trading at a discount compared to its peers' average historical valuations, which may attract investors looking for value. <BR><BR>However, it is important to note that despite the recent rise, the stock has experienced a decline of 16.13% over the past year and has shown weak long-term fundamental strength, with a low average ROCE of 5.21% and poor growth in net sales. This mixed performance indicates that while there are short-term gains, the long-term outlook remains uncertain.